The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial

 

Show simple item record

dc.contributor.author Randell, Elizabeth
dc.contributor.author McNamara, Rachel
dc.contributor.author Davies, D Mark
dc.contributor.author Owen-Jones, Eleri
dc.contributor.author Kirby, Nigel
dc.contributor.author Angel, Lianna
dc.contributor.author Drew, Cheney
dc.contributor.author Cannings-John, Rebecca
dc.contributor.author Smalley, Michelle
dc.contributor.author Saxena, Anurag
dc.contributor.author McDermott, Emer
dc.contributor.author Stockwell, Laura
dc.contributor.author de Vries, Petrus J
dc.contributor.author Hood, Kerry
dc.contributor.author Sampson, Julian R
dc.date.accessioned 2016-08-17T07:38:46Z
dc.date.available 2016-08-17T07:38:46Z
dc.date.issued 2016-08-11
dc.identifier.citation Randell, E., McNamara, R., Davies, D. M., Owen-Jones, E., Kirby, N., Angel, L., ... & McDermott, E. (2016). The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. Trials, 17(1):39. en_ZA
dc.identifier.issn 1745-6215 en_ZA
dc.identifier.uri http://dx.doi.org/10.1186/s13063-016-1446-6
dc.identifier.uri http://hdl.handle.net/11427/21277
dc.description.abstract Background: Tuberous sclerosis complex (TSC) is a genetic disorder affecting about 1 in 6000 people and is characterised by the development of tumours in many organs, including the skin and kidneys, and by a range of neurological and neuropsychiatric manifestations. TSC-associated neuropsychiatric disorders (TAND) occur in the majority of those with TSC, and they have a significant impact on patients and their families, given the everyday impact of TAND on education, employment, family and social life. The potential benefits of better treatment for TAND therefore include reduction in health care demands and wider benefits for patients and their carers. Methods/design: We have planned a single-centre, two-arm, individually randomised, phase II, double-blind, placebo-controlled trial of everolimus versus placebo in the treatment of neurocognitive problems in patients with tuberous sclerosis. Everolimus is a licensed medicine in this patient group, but for a different target of effect. The present trial is a proof-of-principle study developed to provide effect size estimates which may be used to inform the design of subsequent trials. Forty-eight patients aged 16–60 years with tuberous sclerosis who have an IQ >60 and a significant deficit (at least −2 SD) in one or more primary outcome measures will be randomly allocated in a ratio of 2:1 to receive everolimus or placebo, respectively. Participants will be assessed for eligibility and then be started on study medication 4 weeks later. They will then be randomised and receive placebo or everolimus for 24 weeks. Neurocognitive and safety assessments will be carried out at baseline and weeks 4, 12, 24 and 36. Discussion: This study is designed to determine the effect sizes of treatment with everolimus or placebo for 6 months on specific neurocognitive functions—recall memory (verbal and non-verbal) and executive function—in people affected by TSC who have significant deficits in these functions. These data will provide new evidence to determine whether larger-scale trials are indicated and to explore suitable outcome measures and analytical methods for neurocognitive trial design. en_ZA
dc.language eng en_ZA
dc.publisher BioMed Central en_ZA
dc.rights Creative Commons Attribution 4.0 International (CC BY 4.0) *
dc.rights.uri http://creativecommons.org/licenses/by/4.0/ en_ZA
dc.source Trials en_ZA
dc.source.uri https://trialsjournal.biomedcentral.com/
dc.title The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial en_ZA
dc.type Journal Article en_ZA
dc.date.updated 2016-08-11T18:02:05Z
dc.language.rfc3066 en
dc.rights.holder Randell et al.
uct.type.publication Research en_ZA
uct.type.resource Article en_ZA
dc.publisher.institution University of Cape Town
dc.publisher.faculty Faculty of Health Sciences en_ZA
dc.publisher.department Department of Psychiatry and Mental Health en_ZA
uct.type.filetype Text
uct.type.filetype Image
dc.identifier.apacitation Randell, E., McNamara, R., Davies, D. M., Owen-Jones, E., Kirby, N., Angel, L., ... Sampson, J. R. (2016). The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. <i>Trials</i>, http://hdl.handle.net/11427/21277 en_ZA
dc.identifier.chicagocitation Randell, Elizabeth, Rachel McNamara, D Mark Davies, Eleri Owen-Jones, Nigel Kirby, Lianna Angel, Cheney Drew, et al "The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial." <i>Trials</i> (2016) http://hdl.handle.net/11427/21277 en_ZA
dc.identifier.vancouvercitation Randell E, McNamara R, Davies DM, Owen-Jones E, Kirby N, Angel L, et al. The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. Trials. 2016; http://hdl.handle.net/11427/21277. en_ZA
dc.identifier.ris TY - Journal Article AU - Randell, Elizabeth AU - McNamara, Rachel AU - Davies, D Mark AU - Owen-Jones, Eleri AU - Kirby, Nigel AU - Angel, Lianna AU - Drew, Cheney AU - Cannings-John, Rebecca AU - Smalley, Michelle AU - Saxena, Anurag AU - McDermott, Emer AU - Stockwell, Laura AU - de Vries, Petrus J AU - Hood, Kerry AU - Sampson, Julian R AB - Background: Tuberous sclerosis complex (TSC) is a genetic disorder affecting about 1 in 6000 people and is characterised by the development of tumours in many organs, including the skin and kidneys, and by a range of neurological and neuropsychiatric manifestations. TSC-associated neuropsychiatric disorders (TAND) occur in the majority of those with TSC, and they have a significant impact on patients and their families, given the everyday impact of TAND on education, employment, family and social life. The potential benefits of better treatment for TAND therefore include reduction in health care demands and wider benefits for patients and their carers. Methods/design: We have planned a single-centre, two-arm, individually randomised, phase II, double-blind, placebo-controlled trial of everolimus versus placebo in the treatment of neurocognitive problems in patients with tuberous sclerosis. Everolimus is a licensed medicine in this patient group, but for a different target of effect. The present trial is a proof-of-principle study developed to provide effect size estimates which may be used to inform the design of subsequent trials. Forty-eight patients aged 16–60 years with tuberous sclerosis who have an IQ >60 and a significant deficit (at least −2 SD) in one or more primary outcome measures will be randomly allocated in a ratio of 2:1 to receive everolimus or placebo, respectively. Participants will be assessed for eligibility and then be started on study medication 4 weeks later. They will then be randomised and receive placebo or everolimus for 24 weeks. Neurocognitive and safety assessments will be carried out at baseline and weeks 4, 12, 24 and 36. Discussion: This study is designed to determine the effect sizes of treatment with everolimus or placebo for 6 months on specific neurocognitive functions—recall memory (verbal and non-verbal) and executive function—in people affected by TSC who have significant deficits in these functions. These data will provide new evidence to determine whether larger-scale trials are indicated and to explore suitable outcome measures and analytical methods for neurocognitive trial design. DA - 2016-08-11 DB - OpenUCT DO - 10.1186/s13063-016-1446-6 DP - University of Cape Town J1 - Trials LK - https://open.uct.ac.za PB - University of Cape Town PY - 2016 SM - 1745-6215 T1 - The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial TI - The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial UR - http://hdl.handle.net/11427/21277 ER - en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution 4.0 International (CC BY 4.0) Except where otherwise noted, this item's license is described as Creative Commons Attribution 4.0 International (CC BY 4.0)